{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:23:58Z","timestamp":1789662238583,"version":"4.0.1"},"reference-count":298,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["IF190676"],"award-info":[{"award-number":["IF190676"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ijbiomac.2025.149664","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T17:04:33Z","timestamp":1766163873000},"page":"149664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P2","title":["Emerging advancements to improve L-asparaginase-based therapy: New insight into old paradigm, a review"],"prefix":"10.1016","volume":"339","author":[{"given":"Bhagyashri Soumya","family":"Nayak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukanya","family":"Samanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyam","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Sonawane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.149664_bb0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.6004\/jnccn.2025.0006","article-title":"Pediatric acute lymphoblastic leukemia, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Inaba","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia","volume":"10","author":"Pagliaro","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0015","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4065\/80.11.1517","article-title":"Adult acute lymphoblastic leukemia","volume":"80","author":"Jabbour","year":"2005","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0020","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of Asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the children\u2019s oncology group","volume":"38","author":"Gupta","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0025","article-title":"Recombinant Erwinia asparaginase (JZP458) in ALL\/LBL: complete follow-up of the Children\u2019s Oncology Group AALL1931 study","author":"Maese","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0030","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"L-asparaginase treatment in acute lymphoblastic leukemia","volume":"117","author":"Pieters","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40164-022-00368-w","article-title":"The emerging scenario of immunotherapy for T-cell acute lymphoblastic leukemia: advances, challenges and future perspectives","volume":"12","author":"Caracciolo","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0040","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0045","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood.2019001557","article-title":"How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children","volume":"135","author":"Teachey","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0050","unstructured":"CureAll framework: WHO global initiative for childhood cancer, (n.d.). https:\/\/www.who.int\/publications-detail-redirect\/9789240025271 (accessed June 3, 2024)."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0055","unstructured":"National Cancer Institute. SEER cancer statistics review, 1975\u20132015: Overview, median age at diagnosis. Accessed July 24, 2025. Available at: https:\/\/seer.cancer.gov\/csr\/1975_2015\/, (accessed July 24, 2025)."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0060","unstructured":"National Cancer Institute. SEER cancer statistics review, 1975\u20132015: Overview, age distribution of incidence cases by site. Accessed July 24, 2025. Available at: https:\/\/seer.cancer.gov\/csr\/1975_ 2015\/, (accessed July 24, 2025)."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0065","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1038\/srep04227","article-title":"Survival improvement by decade of patients aged 0\u201314 years with acute lymphoblastic leukemia: a SEER analysis","volume":"4","author":"Ma","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0070","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2008-06-164863","article-title":"Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century","volume":"113","author":"Pulte","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0075","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2016-11-749507","article-title":"Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis","volume":"129","author":"Geyer","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0080","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","article-title":"Outcomes in older adults with acute lymphoblastic leukemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial","volume":"157","author":"Sive","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0085","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 protocol: results from an international phase III randomized study","volume":"37","author":"Pieters","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025, CA","volume":"75","author":"Siegel","year":"2025","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.bvth.2025.100065","article-title":"Real-world analysis of strategies to prevent thrombosis and bleeding in adults with ALL treated with asparaginase","volume":"2","author":"Mort","year":"2025","journal-title":"Blood Vessels Thromb. Hemost."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1392099","article-title":"Asparaginase-specific basophil recognition and activation predict Asparaginase hypersensitivity in mice","volume":"15","author":"Rathod","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0105","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/pbc.22076","article-title":"Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis","volume":"53","author":"Kearney","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0110","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","article-title":"The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols","volume":"152","author":"Grace","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0115","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pbc.25319","article-title":"On behalf of the Nordic Society of Paediatric Haematology and Oncology (NOPHO) group, PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol","volume":"62","author":"Henriksen","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0120","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/MPH.0b013e3181e6f003","article-title":"Tolerability and efficacy of L-Asparaginase therapy in pediatric patients with acute lymphoblastic leukemia","volume":"32","author":"Raetz","year":"2010","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0125","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood.2022016923","article-title":"Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2\/3 AALL1931 study","volume":"141","author":"Maese","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0130","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/pbc.21980","article-title":"Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia","volume":"52","author":"Lowas","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0135","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3109\/10428194.2015.1101098","article-title":"Asparaginase-associated toxicity in children with acute lymphoblastic leukemia","volume":"57","author":"Hijiya","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0140","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1182\/blood-2013-10-535112","article-title":"The glutaminase activity of l-asparaginase is not required for anticancer activity against ASNS-negative cells","volume":"123","author":"Chan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0145","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/s41598-018-38094-1","article-title":"Microbes producing L-Asparaginase free of Glutaminase and urease isolated from extreme locations of Antarctic soil and Moss","volume":"9","author":"Ashok","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0150","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/1097-0142(197002)25:2<253::AID-CNCR2820250204>3.0.CO;2-U","article-title":"Toxicity of E. Coli L-asparaginase in man","volume":"25","author":"Oettgen","year":"1970","journal-title":"Cancer"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0155","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/0006-2952(69)90329-3","article-title":"Glutaminase activity of L-asparagine amidohydrolase","volume":"18","author":"Miller","year":"1969","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0160","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/1097-0142(197601)37:1<220::AID-CNCR2820370132>3.0.CO;2-W","article-title":"Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia","volume":"37","author":"Killander","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0165","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000095827","article-title":"Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-Asparaginase","volume":"74","author":"Bodmer","year":"2006","journal-title":"Digestion"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0170","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2018.00212","article-title":"Development of L-asparaginase biobetters: current research status and review of the desirable quality profiles","volume":"6","author":"Brumano","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0180","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.3390\/molecules25245827","article-title":"Recent strategies and applications for l-Asparaginase confinement","volume":"25","author":"Nunes","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121796","article-title":"Co-encapsulation of l-asparaginase and etoposide in dextran nanoparticles for synergistic effect in chronic myeloid leukemia cells","volume":"622","author":"Konh\u00e4user","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0190","series-title":"Lang: Uber desamidierung im Tierkorper","year":"1904"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0195","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1084\/jem.98.6.565","article-title":"Regression of transplanted lymphomas induced in vivo by means of normal Guinea pig serum\u00a0: I. Course of transplanted cancers of various kinds in mice and rats given Guinea pig serum, Horse serum, or Rabbit serum","volume":"98","author":"Kidd","year":"1953","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0200","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.118.1.99","article-title":"Evidence that the L-asparaginase of Guinea pig serum is responsible for its antilymphoma effects\u00a0: I. Properties of the L-asparaginase of Guinea pig serum in relation to those of the antilymphoma substance","volume":"118","author":"Broome","year":"1963","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0205","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.124.3212.124","article-title":"Dual requirement of Walker Carcinosarcoma 256 in vitro for asparagine and glutamine","volume":"124","author":"Neuman","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0210","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0003-9861(64)90032-3","article-title":"Tumor inhibitory effect of l-asparaginase from Escherichia coli","volume":"105","author":"Mashburn","year":"1964","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0215","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0140-6736(68)90977-X","article-title":"A new l-ASPARAGINASE with antitumour activity","volume":"292","author":"Wade","year":"1968","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0220","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/1097-0142(197002)25:2<279::AID-CNCR2820250205>3.0.CO;2-7","article-title":"Clinical results of treatment with E. Coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors","volume":"25","author":"Clarkson","year":"1970","journal-title":"Cancer"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0225","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1111\/febs.16042","article-title":"Structural and biochemical properties of L-asparaginase","volume":"288","author":"Lubkowski","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0230","first-page":"40214","article-title":"Characterization of mycobacterium smegmatis glutaminase-free asparaginase (MSMEG_3173)","volume":"9","author":"Rezende Corr\u00eaa","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217404","article-title":"A human-like glutaminase-free asparaginase is highly efficacious in ASNSlow leukemia and solid cancer mouse xenograft models","volume":"611","author":"Van Trimpont","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0240","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1182\/blood-2024-200575","article-title":"Safety and efficacy of Asparaginase therapy in pediatric patients with previous associated serious adverse reactions under the guidance of asparagine concentration monitoring","volume":"144","author":"Yin","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0245","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1269282","article-title":"Desirable L-asparaginases for treating cancer and current research trends","volume":"15","author":"Tsegaye","year":"2024","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0250","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejphar.2015.12.023","article-title":"L-asparaginase as a critical component to combat acute lymphoblastic Leukaemia (ALL): a novel approach to target ALL","volume":"771","author":"Ali","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0255","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1107\/S2052252521006011","article-title":"Structural and biophysical aspects of l-asparaginases: a growing family with amazing diversity","volume":"8","author":"Loch","year":"2021","journal-title":"IUCrJ"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0260","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1158\/1535-7163.MCT-18-1329","article-title":"Glutaminase activity of L-Asparaginase contributes to durable preclinical activity against acute lymphoblastic leukemia","volume":"18","author":"Chan","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0265","first-page":"2619","article-title":"Inhibition of leukemias in man by L-asparaginase","volume":"27","author":"Oettgen","year":"1967","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0270","doi-asserted-by":"crossref","first-page":"8462","DOI":"10.1021\/acscatal.5c01608","article-title":"Reversible substrate-specific Photocontrol of the chemotherapeutic Asparaginase(\u2212Glutaminase) from Escherichia coli","volume":"15","author":"Wieland","year":"2025","journal-title":"ACS Catal."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0275","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/s42255-025-01245-6","article-title":"Asparagine deprivation enhances T cell antitumour response in patients via ROS-mediated metabolic and signal adaptations","volume":"7","author":"Chang","year":"2025","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0280","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1126\/science.160.3827.533","article-title":"Asparagine Synthetase activity of mouse Leukemias","volume":"160","author":"Horowitz","year":"1968","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0285","doi-asserted-by":"crossref","first-page":"17664","DOI":"10.1074\/jbc.M116.728485","article-title":"Design and characterization of Erwinia Chrysanthemi l-Asparaginase variants with diminished l-Glutaminase activity","volume":"291","author":"Nguyen","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0290","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.19.02292","article-title":"Individualized Asparaginase dosing in childhood acute lymphoblastic leukemia","volume":"38","author":"Kloos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0295","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"van der Sluis","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0300","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1080\/10428194.2018.1542146","article-title":"Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on children\u2019s oncology group AALL07P4*","volume":"60","author":"Schore","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0305","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/cpdd.1002","article-title":"Population pharmacokinetic model development and simulation for recombinant Erwinia Asparaginase produced in Pseudomonas fluorescens (JZP-458)","volume":"10","author":"Lin","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0310","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/cts.13499","article-title":"Population pharmacokinetics of intramuscular recombinant Erwinia chrysanthemi asparaginase (JZP458) in patients with acute lymphoblastic leukemia","volume":"16","author":"Lin","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2024.1381032","article-title":"Probing the active site of class 3 L-asparaginase by mutagenesis. I. Tinkering with the zinc coordination site of ReAV","volume":"12","author":"Pokrywka","year":"2024","journal-title":"Front. Chem."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0320","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1021\/bi00855a011","article-title":"Two L-asparaginases from Escherichia coli B. Their separation, purification, and antitumor activity","volume":"6","author":"Campbell","year":"1967","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0325","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jmb.2006.04.066","article-title":"Crystal structure of plant Asparaginase","volume":"360","author":"Michalska","year":"2006","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0330","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1073\/pnas.90.4.1474","article-title":"Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy","volume":"90","author":"Swain","year":"1993","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0335","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1634\/theoncologist.12-8-991","article-title":"FDA drug approval summary: Pegaspargase (Oncaspar\u00ae) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)","volume":"12","author":"Dinndorf","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0340","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1517\/14712598.2012.718327","article-title":"Erwinia asparaginase in pediatric acute lymphoblastic leukemia","volume":"12","author":"Salzer","year":"2012","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0345","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1021\/bi0029595","article-title":"Structural basis for the activity and substrate specificity of Erwinia chrysanthemi l-Asparaginase","volume":"40","author":"Aghaiypour","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0350","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0014-5793(96)00660-6","article-title":"A covalently bound catalytic intermediate in Escherichia coli asparaginase: crystal structure of a Thr-89-Val mutant","volume":"390","author":"Palm","year":"1996","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0355","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jmb.2014.04.016","article-title":"Elucidation of the specific function of the conserved threonine triad responsible for human L-asparaginase autocleavage and substrate hydrolysis*","volume":"426","author":"Nomme","year":"2014","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0360","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3109\/07388551.2015.1120705","article-title":"Therapeutic l-asparaginase: upstream, downstream and beyond","volume":"37","author":"Lopes","year":"2017","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0365","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.1021\/acscatal.4c07791","article-title":"Unveiling the catalytic mechanism and conformational dynamics of Guinea pig l-Asparaginase type 1 for leukemia drug design","volume":"15","author":"Andjelkovic","year":"2025","journal-title":"ACS Catal."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0370","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1208277","article-title":"Current state of molecular and metabolic strategies for the improvement of L-asparaginase expression in heterologous systems","volume":"14","author":"Lefin","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0375","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/cts.12947","article-title":"A randomized phase I study to evaluate the safety, tolerability, and pharmacokinetics of recombinant Erwinia Asparaginase (JZP-458) in healthy adult volunteers","volume":"14","author":"Lin","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0380","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.leu.2400834","article-title":"Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase","volume":"11","author":"Ueno","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2015.01.002","article-title":"Recent developments in l-asparaginase discovery and its potential as anticancer agent","volume":"100","author":"Shrivastava","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0390","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/jam.14623","article-title":"L-asparaginase production and enhancement by Sarocladium strictum: in vitro evaluation of anti-cancerous properties","volume":"129","author":"Golbabaie","year":"2020","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0395","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1038\/s41598-020-64052-x","article-title":"Bioprocess development for L-asparaginase production by Streptomyces rochei, purification and in-vitro efficacy against various human carcinoma cell lines","volume":"10","author":"El-Naggar","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0400","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s12033-016-9950-1","article-title":"The modified heparin-binding l-Asparaginase of Wolinella succinogenes","volume":"58","author":"Sannikova","year":"2016","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0405","doi-asserted-by":"crossref","first-page":"31222","DOI":"10.1016\/S0021-9258(19)84035-8","article-title":"Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-Asparaginase*","volume":"281","author":"Reinert","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0410","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4236\/aim.2012.22019","article-title":"Purification and biochemical characterization of native and Pegylated form of L-Asparaginase from aspergillus terreus and evaluation of its Antiproliferative activity","volume":"2","author":"Loureiro","year":"2012","journal-title":"Adv. Microbiol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0415","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/2277-9175.127995","article-title":"Cloning, expression, purification and characterisation of Erwinia carotovora L-asparaginase in Escherichia coli","volume":"3","author":"Pourhossein","year":"2014","journal-title":"Adv. Biomed. Res."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117025","article-title":"Engineering of helicobacter pylori L-Asparaginase: characterization of two functionally distinct groups of mutants","volume":"10","author":"Maggi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099037","article-title":"Purification and characterization of a novel and robust L-asparaginase having low-glutaminase activity from Bacillus licheniformis: in vitro evaluation of anti-cancerous properties","volume":"9","author":"Mahajan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0430","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.4014\/jmb.1510.10092","article-title":"A newly identified glutaminase-free L-asparaginase (L-ASPG86) from the marine bacterium Mesoflavibacter zeaxanthinifaciens","volume":"26","author":"Lee","year":"2016","journal-title":"J. Microbiol. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0435","doi-asserted-by":"crossref","first-page":"498","DOI":"10.18097\/pbmc20135905498","article-title":"Antitumor activity of L-asparaginase from Erwinia carotovora from against different leukemic and solid tumours cell lines","volume":"59","author":"Abakumova","year":"2013","journal-title":"Biomed. Khim."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178174","article-title":"The human asparaginase enzyme (ASPG) inhibits growth in leukemic cells","volume":"12","author":"Belviso","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0445","doi-asserted-by":"crossref","first-page":"26759","DOI":"10.1038\/s41598-025-08962-8","article-title":"Tapping the untapped: type II L-asparaginase from marine crustacean-derived Chryseomicrobium amylolyticum as a potential bio better for blood cancer therapy","volume":"15","author":"Lailaja","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0336433","article-title":"Enzymatic properties of a L-asparaginase without secondary glutaminase activity from Streptomyces scabrisporus","volume":"20","author":"Rodr\u00edguez-Vargas","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0455","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1080\/09168451.2020.1807310","article-title":"L-Asparaginase activity analysis, ansZ gene identification and anticancer activity of a new Bacillus subtilis isolated from sponges of the Red Sea","volume":"84","author":"Ameen","year":"2020","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0460","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.576511","article-title":"L-asparaginase production by Leucosporidium scottii in a bench-scale bioreactor with co-production of lipids","volume":"8","author":"Moguel","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0465","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/10826068.2019.1692221","article-title":"Production, purification and kinetic characterization of glutaminase free anti-leukemic L-asparaginase with low endotoxin level from novel soil isolate","volume":"50","author":"Prakash","year":"2020","journal-title":"Prep. Biochem. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0470","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1038\/s41598-019-40512-x","article-title":"Production and anticancer activity of an L-Asparaginase from Bacillus licheniformis isolated from the Red Sea, Saudi Arabia","volume":"9","author":"Alrumman","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0475","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1080\/07391102.2020.1851300","article-title":"Purification and biotechnological applications of L-asparaginase from newly isolated Bacillus halotolerans OHEM18 as antitumor and antioxidant agent","volume":"40","author":"El-Fakharany","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0480","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12934-025-02855-1","article-title":"Characterization and bioactivities of glutaminase-free L-asparaginase from Salinicola acorporae S4-41","volume":"24","author":"El-Shanshoury","year":"2025","journal-title":"Microb. Cell Factories"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0485","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ijbiomac.2020.02.246","article-title":"Characterization of a thermostable, allosteric L-asparaginase from Anoxybacillus flavithermus","volume":"152","author":"Maqsood","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0490","doi-asserted-by":"crossref","DOI":"10.1038\/srep36239","article-title":"Recombinant L-asparaginase 1 from Saccharomyces cerevisiae: an allosteric enzyme with antineoplastic activity","volume":"6","author":"Costa","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0495","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ijbiomac.2018.12.162","article-title":"Production and structural modeling of a novel asparaginase in Yarrowia lipolytica","volume":"125","author":"Darvishi","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0500","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12866-025-03833-8","article-title":"L-asparaginase from the novel fusarium falciforme AUMC 16563: extraction, purification, characterization, and cytotoxic effects on PC-3, HePG-2, HCT-116, and MCF-7 cell lines","volume":"25","author":"Saleh","year":"2025","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0505","doi-asserted-by":"crossref","DOI":"10.18502\/ajmb.v17i3.19275","article-title":"Characterization and evaluation of the anti-proliferative activity and hypersensitivity of L-asparaginase from Trichosporon asahii isolate ChL11 and Candida palmioleophila isolate JK12","author":"Sisay","year":"2025","journal-title":"Avicenna J. Med. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0510","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s43141-023-00493-x","article-title":"Therapeutic impact of purified Trichoderma viride L-asparaginase in murine model of liver cancer and in vitro Hep-G2 cell line","volume":"21","author":"El-Ghonemy","year":"2023","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0515","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1080\/10242422.2025.2470140","article-title":"Purification and characterization of the L-asparaginase enzyme derived from aspergillus flavus HK03 along with its anti-proliferative activity","volume":"43","author":"Luhana","year":"2025","journal-title":"Biocatal. Biotransformation"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0520","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijbiomac.2019.12.156","article-title":"The effect of Yarrowia lipolytica l-asparaginase on apoptosis induction and inhibition of growth in Burkitt\u2019s lymphoma Raji and acute lymphoblastic leukemia MOLT-4 cells","volume":"146","author":"Mazloum-Ravasan","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0525","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.procbio.2023.03.003","article-title":"Antarctic yeasts as a source of L-asparaginase: characterization of a glutaminase-activity free L-asparaginase from psychrotolerant yeast Leucosporidium scottii L115","volume":"129","author":"S\u00e1nchez-Moguel","year":"2023","journal-title":"Process Biochem."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0530","first-page":"2540","article-title":"Production, purification, characterization, antioxidant and antiproliferative activities of extracellular L-asparaginase produced by fusarium equiseti AHMF4, Saudi","volume":"28","author":"El-Gendy","year":"2021","journal-title":"Aust. J. Biol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0535","first-page":"185","article-title":"Comparative analysis of purified anti-leukemic L-asparaginase enzyme from Trichoderma spp","volume":"11","author":"Luhana","year":"2023","journal-title":"J. Appl. Biol. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0540","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.apjtb.2016.07.007","article-title":"Purification, characterization and antiproliferative activity of l-asparaginase from Aspergillus oryzae CCT 3940 with no glutaminase activity","volume":"6","author":"Dias","year":"2016","journal-title":"Asian Pac. J. Trop. Biomed."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0545","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s42770-023-00939-x","article-title":"A new extracellular glutaminase and urease-free l-asparaginase from Meyerozyma guilliermondii","volume":"54","author":"Ratuchne","year":"2023","journal-title":"Braz. J. Microbiol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0550","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.3390\/pharmaceutics13111965","article-title":"Encapsulation of Asparaginase as a promising strategy to improve in vivo drug performance","volume":"13","author":"Villanueva-Flores","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0555","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","article-title":"Comparative pharmacokinetic studies of three asparaginase preparations","volume":"11","author":"Asselin","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0560","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/1097-0142(19950301)75:5<1176::AID-CNCR2820750519>3.0.CO;2-Y","article-title":"An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia","volume":"75","author":"Ettinger","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0565","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a children\u2019s Cancer group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0570","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1158\/1078-0432.CCR-19-1255","article-title":"FDA approval summary: calaspargase pegol-mknl for treatment of acute lymphoblastic leukemia in children and young adults","volume":"26","author":"Li","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0575","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0580","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1080\/10428194.2019.1608530","article-title":"A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage","volume":"60","author":"Marini","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0585","article-title":"A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia, Pediatr. Blood","volume":"66","author":"Kloos","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0590","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29169","article-title":"Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?","volume":"68","author":"Maese","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0595","doi-asserted-by":"crossref","first-page":"TPS7568","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS7568","article-title":"A phase II\/III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)\/lymphoblastic lymphoma (LBL) who are hypersensitive to E. Coli-derived asparaginases","volume":"38","author":"Maese","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0600","unstructured":"Rylaze (Asparaginase erwinia chrysanthemi (Recombinant)-Rywn) Injection, for Intramuscular Use Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc., (n.d.). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761179s001lbl.pdf."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0605","author":"C. for D.E. and Research"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0610","series-title":"Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday\/Wednesday\/Friday Intramuscular Dosing Schedule for Rylaze\u00ae (asparaginase erwinia chrysanthemi (recombinant)-rywn)","year":"2024"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0615","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1200\/JCO.20.03692","article-title":"Efficacy and toxicity of Pegaspargase and Calaspargase Pegol in childhood acute lymphoblastic leukemia: results of DFCI 11-001","volume":"39","author":"Vrooman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0620","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/bloodadvances.2024015455","article-title":"Desensitization to calaspargase pegol appears to be less successful than pegaspargase","volume":"9","author":"Matherne","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0625","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mpo.2950130105","article-title":"Height of children successfully treated for acute lymphoblastic leukemia: a report from the late effects study committee of childrens cancer study group","volume":"13","author":"Robison","year":"1985","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0630","unstructured":"Elspar (asparaginase) [prescribing information].Deerfield (IL): Lundbeck, (n.d.). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/101063s5169lbl.pdf."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0635","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood-2009-09-245951","article-title":"Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia","volume":"115","author":"Silverman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0640","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28719","article-title":"Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL consortium protocols 05-001 and 11-001","volume":"68","author":"Burns","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0645","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1182\/blood-2021-149463","article-title":"Safety and pharmacokinetics of Calaspargase Pegol in adults with newly diagnosed Philadelphia-negative ALL: a phase 2\/3 study","volume":"138","author":"Stock","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0650","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/pbc.25757","article-title":"Activity and toxicity of intravenous Erwinia asparaginase following allergy to E. coli-derived asparaginase in children and adolescents with acute lymphoblastic leukemia","volume":"63","author":"Vrooman","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0655","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-147023","article-title":"Initial results from a phase 2\/3 study of recombinant Erwinia asparaginase (JZP458) in patients with acute lymphoblastic leukemia (ALL)\/lymphoblastic lymphoma (LBL) who are allergic\/hypersensitive to E. coli-derived asparaginases","volume":"138","author":"Maese","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0660","first-page":"535","article-title":"L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia","volume":"37","author":"Ortega","year":"1977","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0665","first-page":"5601","article-title":"Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia","volume":"43","author":"Sallan","year":"1983","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0670","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.leu.2401310","article-title":"Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a pediatric oncology group study","volume":"13","author":"Amylon","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0675","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","article-title":"Long-term results of a randomized trial on extended use of high dose l-Asparaginase for standard risk childhood acute lymphoblastic leukemia","volume":"23","author":"Pession","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0680","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1182\/blood.V96.5.1709","article-title":"Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study","volume":"96","author":"Abshire","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0685","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber consortium protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0690","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/blood-2007-02-070342","article-title":"Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the children\u2019s oncology group","volume":"111","author":"Seibel","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0695","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and high-dose methotrexate improve outcome for children and Young adults with high-risk B-acute lymphoblastic leukemia: a report from children\u2019s oncology group study AALL0232","volume":"34","author":"Larsen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0700","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved survival for children and Young adults with T-lineage acute lymphoblastic leukemia: results from the children\u2019s oncology group AALL0434 methotrexate randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0705","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2007.13.7265","article-title":"Comparison of the results of the treatment of adolescents and Young adults with standard-risk acute lymphoblastic leukemia with the Programa Espa\u00f1ol de Tratamiento en Hematolog\u00eda pediatric-based protocol ALL-96","volume":"26","author":"Ribera","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0710","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome\u2013negative acute lymphoblastic leukemia: the GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0715","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood.V116.21.494.494","article-title":"PEG-Asparaginase intensification in adult acute lymphoblastic leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity in the German multicenter study Group for Adult ALL (GMALL) study 07\/2003","volume":"116","author":"Goekbuget","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0720","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2017.76.8192","article-title":"For the Group of Research on adult ALL (GRAALL), intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial","volume":"36","author":"Huguet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0725","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1200\/JCO.2013.50.2708","article-title":"Pharmacokinetics-based integration of multiple doses of intravenous Pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia","volume":"32","author":"Douer","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0730","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18\u201350 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0735","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0740","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1\u201345 years with acute lymphoblastic leukemia","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0745","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24419","article-title":"Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin\u2013Frankfurt\u2013M\u00fcnster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen","volume":"91","author":"Rytting","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0750","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.3324\/haematol.2020.251686","article-title":"Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"106","author":"Geyer","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0755","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1606261","article-title":"Risk factors and outcome of asparaginase-associated pancreatitis in pediatric acute lymphoblastic leukemia","volume":"15","author":"Hassan","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0760","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/BLCTT.S342052","article-title":"Asparaginase in the treatment of acute lymphoblastic leukemia in adults: current evidence and Place in therapy","volume":"12","author":"Juluri","year":"2022","journal-title":"Blood Lymphat. Cancer Targets Ther."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0765","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","article-title":"Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel","volume":"52","author":"Stock","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0770","unstructured":"Acute Lymphoblastic Leukemia Version 1.2023, NCCN Clinical Practice Guidelines in Oncology, (n.d.). https:\/\/raghavhealthcare.in\/files\/documents\/c57adce2-7df0-49aa-acf4-dc17507d7c6a.pdf."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0775","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1182\/blood.2019002132","article-title":"How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia","volume":"135","author":"Aldoss","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0780","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.clml.2021.07.009","article-title":"SOHO state of the art updates and next questions: Management of Asparaginase Toxicity in adolescents and Young adults with acute lymphoblastic leukemia","volume":"21","author":"Schmiegelow","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0785","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/S2152-2650(21)01224-6","article-title":"Asparaginase: understanding and overcoming toxicities","volume":"21","author":"Aldoss","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0790","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/bjh.12733","article-title":"Nordic Society of Paediatric Haematology and Oncology (NOPHO) group, Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol","volume":"165","author":"Raja","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0795","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S1470-2045(17)30424-2","article-title":"Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno toxicity working group study","volume":"18","author":"Wolthers","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0800","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2018-01-827949","article-title":"Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years","volume":"131","author":"Rank","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0805","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11912-022-01345-6","article-title":"Asparaginase: how to better manage toxicities in adults","volume":"25","author":"Pourhassan","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0810","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jha2.607","article-title":"Safety of re-challenging adults with acute lymphoblastic leukemia with PEG-asparaginase-induced severe hypertriglyceridemia when treated with a pediatric-inspired regimen","volume":"4","author":"Al Nabhani","year":"2023","journal-title":"eJHaem"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111616","article-title":"Circumventing the side effects of L-asparaginase","volume":"139","author":"Fonseca","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0820","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaci.2007.07.033","article-title":"Anaphylaxis: lessons from mouse models","volume":"120","author":"Finkelman","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0825","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/leu.2012.102","article-title":"Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia","volume":"26","author":"Liu","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0830","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.2000.18.7.1525","article-title":"Hypersensitivity or development of antibodies to Asparaginase Does not impact treatment outcome of childhood acute lymphoblastic leukemia","volume":"18","author":"Woo","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0835","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.immuni.2008.02.008","article-title":"Basophils play a pivotal role in immunoglobulin-G-mediated but not immunoglobulin-E-mediated systemic anaphylaxis","volume":"28","author":"Tsujimura","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0840","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1067\/mai.2002.123302","article-title":"Pathways of anaphylaxis in the mouse","volume":"109","author":"Strait","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0845","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1124\/jpet.114.220780","article-title":"Effect of Premedications in a murine model of Asparaginase hypersensitivity","volume":"352","author":"Fernandez","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0850","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3324\/haematol.2018.199448","article-title":"Hypersensitivity reactions to asparaginase in mice are mediated by anti-asparaginase IgE and IgG and the immunoglobulin receptors Fc\u03b5RI and Fc\u03b3RIII","volume":"104","author":"Rathod","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0855","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26873","article-title":"Outcome of pediatric patients with acute lymphoblastic leukemia\/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: a report from the children's oncology group","volume":"65","author":"Rau","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0860","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/25379","article-title":"An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation","volume":"396","author":"Manoury","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0865","first-page":"1964","article-title":"A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug l-asparaginase","volume":"119","author":"Patel","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0870","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2217\/fon-2021-1288","article-title":"Hypersensitivity reactions to Asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences","volume":"18","author":"Burke","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0875","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bjhh.2016.11.006","article-title":"Do immunoglobulin G and immunoglobulin E anti-l-asparaginase antibodies have distinct implications in children with acute lymphoblastic leukemia? A cross-sectional study","volume":"39","author":"Galindo-Rodr\u00edguez","year":"2017","journal-title":"Rev. Bras. Hematol. E Hemoter."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0880","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2014-03-563742","article-title":"HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies","volume":"124","author":"Fernandez","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0885","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1182\/blood-2015-02-628800","article-title":"Genome-wide analysis links NFATC2 with asparaginase hypersensitivity","volume":"126","author":"Fernandez","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0890","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/clpt.2010.94","article-title":"Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity","volume":"88","author":"Chen","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0895","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2399","article-title":"Protein therapeutics: a summary and pharmacological classification","volume":"7","author":"Leader","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0900","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to biotherapeutics \u2013 the role of anti-drug immune complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0905","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1385\/MB:33:1:57","article-title":"Probing the antigenicity of E. Coli l-asparaginase by mutational analysis","volume":"33","author":"Jianhua","year":"2006","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0910","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1042\/bj3020921","article-title":"Erwinia chrysanthemi l -asparaginase: epitope mapping and production of antigenically modified enzymes","volume":"302","author":"Moola","year":"1994","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0915","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1073\/pnas.1014739108","article-title":"Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift","volume":"108","author":"Cantor","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0920","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2014-03-563742","article-title":"HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies","volume":"124","author":"Fernandez","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0925","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00280-017-3459-6","article-title":"Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed\/refractory acute myeloid leukemia","volume":"81","author":"Emadi","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217242","article-title":"Rewired glutamate metabolism diminishes cytostatic action of L-asparaginase","volume":"605","author":"Hlozkova","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0935","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.3390\/nu10111564","article-title":"Glutamine: metabolism and immune function, supplementation and clinical translation","volume":"10","author":"Cruzat","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0940","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.3324\/haematol.2014.109413","article-title":"The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia","volume":"99","author":"Tong","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0945","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202500945","article-title":"An integrated method to evaluate the treatment efficacy and immunogenicity of B-cell acute lymphoblastic leukemia therapeutic enzyme formulations","author":"Santelli","year":"2025","journal-title":"Small Methods"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0950","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.htct.2019.07.010","article-title":"Asparaginase: an old drug with new questions","volume":"42","author":"Cecconello","year":"2020","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0955","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/bjc.2014.425","article-title":"Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts","volume":"111","author":"Chiu","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0960","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood-2010-07-298422","article-title":"Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity","volume":"117","author":"Offman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0965","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.leukres.2015.04.008","article-title":"Glutaminase activity determines cytotoxicity of L-Asparaginases on Most leukemia cell lines","volume":"39","author":"Parmentier","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0970","first-page":"1121","article-title":"Deamination of glutamine is a prerequisite for optimal asparagine deamination by Asparaginases in vivo (CCG-1961)","volume":"24","author":"Panosyan","year":"2004","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0975","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1158\/0008-5472.CAN-17-2106","article-title":"A novel L-asparaginase with low L-glutaminase coactivity is highly efficacious against both T and B cell acute lymphoblastic leukemias in vivo","volume":"78","author":"Nguyen","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0980","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn6491","article-title":"Tumoral microenvironment prevents de novo asparagine biosynthesis in B cell lymphoma, regardless of ASNS expression","volume":"8","author":"Grima-Reyes","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0985","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3324\/haematol.2022.281390","article-title":"In vivo stabilization of a less toxic asparaginase variant leads to a durable antitumor response in acute leukemia","volume":"108","author":"Trimpont","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0990","first-page":"957","article-title":"Effect of administration of the enzyme GLUTAMINASE on the growth of CANCER cells","volume":"24","author":"Greenberg","year":"1964","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb0995","first-page":"116","article-title":"Studies on the mechanism of inhibition of tumor growth by the enzyme glutaminase","volume":"26","author":"el-Asmar","year":"1966","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1000","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/jam.14221","article-title":"Screening and optimizing fermentation production of l-asparaginase by aspergillus terreus strain S-18 isolated from the Brazilian Caatinga biome","volume":"126","author":"da Rocha","year":"2019","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1005","first-page":"1479","article-title":"Clinical evaluation of succinylated Acinetobacter glutaminase-asparaginase in adult leukemia","volume":"66","author":"Warrell","year":"1982","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1010","article-title":"The differential ability of asparagine and glutamine in promoting the closed\/active enzyme conformation rationalizes the Wolinella succinogenes L-asparaginase substrate specificity","volume":"7","author":"Nguyen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1015","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1038\/s41598-021-84949-5","article-title":"Bioprospecting of the agaricomycete Ganoderma australe GPC191 as novel source for l-asparaginase production","volume":"11","author":"Chakraborty","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1020","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nbt0910-917","article-title":"Biopharmaceutical benchmarks 2010","volume":"28","author":"Walsh","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1025","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1074\/jbc.M113.486530","article-title":"Mutations in subunit Interface and B-cell epitopes improve Antileukemic activities of Escherichia coli Asparaginase-II","volume":"289","author":"Mehta","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.mehy.2018.01.004","article-title":"Novel mutant of Escherichia coli asparaginase II to reduction of the glutaminase activity in treatment of acute lymphocytic leukemia by molecular dynamics simulations and QM-MM studies","volume":"112","author":"Ardalan","year":"2018","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1035","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.101909","article-title":"Preclinical evaluation of engineered L-asparaginase variants to improve the treatment of acute lymphoblastic leukemia","volume":"43","author":"Sengupta","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1040","first-page":"1","article-title":"Engineered L-asparaginase variants with enhanced therapeutic properties to improve treatment of childhood acute lymphatic leukemia","author":"Biswas","year":"2025","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1045","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1182\/blood-2021-150857","article-title":"Pre-clinical evaluation of novel L-Asparaginase mutants for the treatment of acute lymphoblastic leukemia","volume":"138","author":"Sengupta","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1050","doi-asserted-by":"crossref","first-page":"902","DOI":"10.3390\/cancers14040902","article-title":"Novel insights on the use of L-Asparaginase as an efficient and safe anti-Cancer therapy","volume":"14","author":"Van Trimpont","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1055","doi-asserted-by":"crossref","first-page":"14479","DOI":"10.1038\/s41598-017-15075-4","article-title":"A protease-resistant Escherichia coli asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro","volume":"7","author":"Maggi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114230","article-title":"Influence of lysosomal protease sensitivity in the immunogenicity of the antitumor biopharmaceutical asparaginase","volume":"182","author":"Rodrigues","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11274-019-2731-9","article-title":"What makes a good new therapeutic L-asparaginase?","volume":"35","author":"Beckett","year":"2019","journal-title":"World J. Microbiol. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1070","first-page":"447","article-title":"Nanodevices for the immobilization of therapeutic enzymes","volume":"36","author":"Bosio","year":"2016","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1075","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1021\/acs.bioconjchem.7b00217","article-title":"Immobilization of l-Asparaginase on carrier materials: a comprehensive review","volume":"28","author":"Ulu","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1080","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.colsurfb.2006.12.019","article-title":"Iron hydroxide nanoparticles coated with poly(ethylene glycol)-poly(aspartic acid) block copolymer as novel magnetic resonance contrast agents for in vivo cancer imaging","volume":"56","author":"Kumagai","year":"2007","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1085","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2165\/00063030-199707010-00005","article-title":"Acute lymphoblastic Leukaemia","volume":"7","author":"Ettinger","year":"1997","journal-title":"BioDrugs"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1090","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1095","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejpb.2013.01.001","article-title":"Nanotoxicological classification system (NCS) \u2013 a guide for the risk-benefit assessment of nanoparticulate drug delivery systems","volume":"84","author":"Keck","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1100","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2023.102915","article-title":"L-Asparaginase delivery systems targeted to minimize its side-effects","volume":"316","author":"Talluri","year":"2023","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.htct.2019.01.013","article-title":"PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review","volume":"42","author":"Medawar","year":"2020","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1110","doi-asserted-by":"crossref","first-page":"17946","DOI":"10.1039\/D4RA02939A","article-title":"Advancements in enzyme immobilization on magnetic nanomaterials: toward sustainable industrial applications","volume":"14","author":"Cavalcante","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1115","first-page":"242","article-title":"Obstacles and pitfalls in the PEGylation of therapeutic proteins","volume":"11","author":"Gaberc-Porekar","year":"2008","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2023.113234","article-title":"L-asparaginase immobilization in supramolecular nanogels of PEG-grafted poly HPMA and bis(\u03b1-cyclodextrin) to enhance pharmacokinetics and lower enzyme antigenicity","volume":"225","author":"Monajati","year":"2023","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1125","doi-asserted-by":"crossref","DOI":"10.1007\/s13205-019-1969-0","article-title":"Impact of immobilization technology in industrial and pharmaceutical applications","volume":"9","author":"Hassan","year":"2019","journal-title":"3 Biotech"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.partic.2023.03.013","article-title":"Micro-sized nanoaggregates: spray-drying-assisted fabrication and applications","volume":"85","author":"Yang","year":"2024","journal-title":"Particuology"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1135","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1038\/s41467-025-60798-y","article-title":"Dual asparagine-depriving nanoparticles against solid tumors","volume":"16","author":"Shen","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1140","doi-asserted-by":"crossref","DOI":"10.1039\/D5BM00138B","article-title":"Peptide hydrogels as slow-release formulations of protein therapeutics: case study of asparaginase-loaded hydrogels","author":"Vu","year":"2025","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1145","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1021\/acscentsci.8b00168","article-title":"Confinement of therapeutic enzymes in selectively permeable polymer vesicles by polymerization-induced self-assembly (PISA) reduces antibody binding and proteolytic susceptibility","volume":"4","author":"Blackman","year":"2018","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1150","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1021\/acsmacrolett.0c00619","article-title":"L-Asparaginase encapsulation into asymmetric permeable polymersomes","volume":"9","author":"Bueno","year":"2020","journal-title":"ACS Macro Lett."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1155","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1021\/acsapm.2c00068","article-title":"L-Asparaginase in situ encapsulated into Zwitterionic Nanocapsules with a prolonged half-life","volume":"4","author":"Zhang","year":"2022","journal-title":"ACS Appl. Polym. Mater."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1160","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1021\/acs.biomac.8b00785","article-title":"Hydrolytically degradable PEGylated polyelectrolyte Nanocomplexes for protein delivery","volume":"19","author":"Andrianov","year":"2018","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1165","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1021\/bm401341k","article-title":"Preserving catalytic activity and enhancing biochemical stability of the therapeutic enzyme Asparaginase by biocompatible multilayered polyelectrolyte microcapsules","volume":"14","author":"Karamitros","year":"2013","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2020.102231","article-title":"Antimicrobial potency evaluation of free and immobilized l-asparaginase using chitosan nanoparticles","volume":"61","author":"Vimal","year":"2021","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1175","doi-asserted-by":"crossref","first-page":"36063","DOI":"10.1039\/C8RA06346J","article-title":"Magnetic-propelled Fe3O4\u2013chitosan carriers enhance L-asparaginase catalytic activity: a promising strategy for enzyme immobilization","volume":"8","author":"Ates","year":"2018","journal-title":"RSC Adv."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1180","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1021\/acs.biomac.6b01870","article-title":"Enzyme-loaded Polyion complex vesicles as in vivo Nanoreactors working sustainably under the blood circulation: characterization and functional evaluation","volume":"18","author":"Sueyoshi","year":"2017","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1185","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2174\/0929867324666170823143634","article-title":"Enhancement in biological activity of L-Asparginase by its conjugation on silica nanoparticles","volume":"12","author":"Golestaneh","year":"2018","journal-title":"Recent Pat. Nanotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1190","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1021\/nl404360k","article-title":"Dual-porosity hollow nanoparticles for the Immunoprotection and delivery of nonhuman enzymes","volume":"14","author":"Ortac","year":"2014","journal-title":"Nano Lett."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1195","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3390\/pharmaceutics13050604","article-title":"Asparaginase-phage P22 Nanoreactors: toward a biobetter development for acute lymphoblastic leukemia treatment","volume":"13","author":"D\u00edaz-Barriga","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1200","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2023.113234","article-title":"L-asparaginase immobilization in supramolecular nanogels of PEG-grafted poly HPMA and bis(\u03b1-cyclodextrin) to enhance pharmacokinetics and lower enzyme antigenicity","volume":"225","author":"Monajati","year":"2023","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1205","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3534807","article-title":"Nanoliposomal L-Asparaginase and its antitumor activities in Lewis lung carcinoma tumor-induced BALB\/c mice","volume":"2019","author":"Do","year":"2019","journal-title":"Adv. Mater. Sci. Eng."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1210","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.colsurfb.2015.03.063","article-title":"Polymer\u2013surfactant complexes for microencapsulation of vitamin E and its release","volume":"137","author":"Sharipova","year":"2016","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1215","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.3390\/molecules23102661","article-title":"Chitosan-based nanomaterials for drug delivery","volume":"23","author":"Li","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1220","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.colsurfb.2017.07.042","article-title":"Polyion complex vesicles (PICsomes) from strong copolyelectrolytes. Stability and in vitro studies","volume":"158","author":"Kwolek","year":"2017","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1225","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.eurpolymj.2016.06.003","article-title":"Polyion complex (PIC) particles: preparation and biomedical applications","volume":"81","author":"Insua","year":"2016","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1230","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/jps.24217","article-title":"Noncovalent PEGylation of l-Asparaginase using PEGylated polyelectrolyte","volume":"104","author":"Kurinomaru","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1235","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.2147\/IJN.S52605","article-title":"Ordered nanoporous silica as carriers for improved delivery of water insoluble drugs: a comparative study between three dimensional and two dimensional macroporous silica","author":"Wang","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1240","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1021\/am302246s","article-title":"Novel chitosan-functionalized spherical Nanosilica matrix as an Oral sustained drug delivery system for poorly water-soluble drug carvedilol","volume":"5","author":"Sun","year":"2013","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1245","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.tibtech.2008.06.009","article-title":"Bioinspired enzyme encapsulation for biocatalysis","volume":"26","author":"Betancor","year":"2008","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1250","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1126\/science.821145","article-title":"Asparaginase entrapped in red blood cells: action and survival","volume":"193","author":"Updike","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1255","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/BF00195932","article-title":"Improved pharmacodynamics of l-asparaginase-loaded in human red blood cells","volume":"49","author":"Kravtzoff","year":"1996","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1260","first-page":"1733","article-title":"Permeability of human erythrocytes to asparagine","volume":"50","author":"Ataullakhanov","year":"1985","journal-title":"Biokhimiia Mosc. Russ."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1265","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1517\/14712598.2012.631909","article-title":"International seminar on the red blood cells as vehicles for drugs","volume":"12","author":"Godfrin","year":"2012","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1270","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1182\/blood.V126.23.3723.3723","article-title":"Updated clinical activity of Graspa versus native l-asparaginase in combination with Cooprall regimen in phase 3 randomized trial in patients with relapsed acute lymphoblastic leukemia (NCT01518517)","volume":"126","author":"Baruchel","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1275","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood.V128.22.1266.1266","article-title":"Red blood cell-encapsulation of L-Asparaginase favorably modulates target selectivity and pharmacodynamics","volume":"128","author":"Lorenzi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1280","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2141.2011.08588.x","article-title":"L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial","volume":"153","author":"Domenech","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1285","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/ajh.24093","article-title":"A phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: the GRASPALL\/GRAALL-SA2-2008 study","volume":"90","author":"Hunault-Berger","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1290","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.7004","article-title":"Drug monitoring of ERY001 (erythrocyte encapsulated L-asparaginase) and native L-asparaginase (L-ASP) in combination with COOPRALL regimen in phase 3 randomized trial in patients with relapsed acute lymphoblastic leukemia","volume":"33","author":"Bertrand","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1295","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjh.18152","article-title":"Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia","volume":"197","author":"Lynggaard","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1300","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40259-020-00415-0","article-title":"Ongoing developments and clinical Progress in drug-loaded red blood cell technologies","volume":"34","author":"Rossi","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1310","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1200\/JCO.2022.40.4_suppl.518","article-title":"Trybeca-1: a randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441)","volume":"40","author":"Hammel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1315","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-139373","article-title":"NOR-GRASPALL2016 (NCT03267030): Asparaginase encapsulated in erythrocytes (eryaspase) - a promising alternative to peg-Asparaginase in case of hypersensitivity","volume":"136","author":"Lynggaard","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1320","unstructured":"ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL | Phaxiam Therapeutics, (n.d.). https:\/\/investors.erytech.com\/news-releases\/news-release-details\/erytech-granted-us-fda-fast-track-designation-eryaspase (accessed October 7, 2024)."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1325","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.biomaterials.2017.09.020","article-title":"Bio-inspired engineering of cell- and virus-like nanoparticles for drug delivery","volume":"147","author":"Parodi","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1330","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15092260","article-title":"A novel formulation of asparaginase encapsulated into virus-like particles of brome mosaic virus: in vitro and in vivo evidence","volume":"15","author":"Villanueva-Flores","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1335","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.colsurfb.2017.07.038","article-title":"Recent applications of PLGA based nanostructures in drug delivery","volume":"159","author":"Mir","year":"2017","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1340","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.msec.2019.01.003","article-title":"Poly (lactic-co-glycolic acid) nanospheres allow for high l-asparaginase encapsulation yield and activity","volume":"C 98","author":"de Brito","year":"2019","journal-title":"Mater. Sci. Eng."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1345","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jsps.2020.04.014","article-title":"Design of expert guided investigation of native L-asparaginase encapsulated long-acting cross-linker-free poly (lactic-co-glycolic) acid nanoformulation in an Ehrlich ascites tumor model","volume":"28","author":"Singh","year":"2020","journal-title":"Saudi Pharm. J. SPJ"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1350","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1021\/acsabm.3c00888","article-title":"Polyoxazoline-conjugated l-Asparaginase: an antibody-production-free therapeutic agent for acute lymphoblastic leukemia","volume":"6","author":"Yamada","year":"2023","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1355","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120606","article-title":"An urchin-like helical polypeptide-asparaginase conjugate with mitigated immunogenicity","volume":"268","author":"Hu","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1360","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122740","article-title":"An ultra-long-acting L-asparaginase synergizes with an immune checkpoint inhibitor in starvation-immunotherapy of metastatic solid tumors","volume":"312","author":"Zhang","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1365","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202501787","article-title":"Thermo-pH-sensitive polypeptides boost protein drug's tumor permeation and pharmacology","author":"Gong","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1370","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4155\/tde-2019-0010","article-title":"Nanogels as drug-delivery systems: a comprehensive overview","volume":"10","author":"Suhail","year":"2019","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1375","first-page":"2963","article-title":"A new era of cancer treatment: carbon nanotubes as drug delivery tools","volume":"6","author":"Madani","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1380","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1007\/s10562-019-03069-y","article-title":"The Carboxylated multi-walled carbon nanotubes\/l-Asparaginase doped calcium-alginate beads: structural and biocatalytic characterization","volume":"150","author":"Ulu","year":"2020","journal-title":"Catal. Lett."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1385","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1021\/acs.bioconjchem.4c00518","article-title":"L-Asparaginase immobilized on Nanographene oxide as an efficient Nanobiocatalytic tool for asparagine depletion in leukemia cells","volume":"36","author":"Erwardt","year":"2025","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1390","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/ab4241","article-title":"Magnetic nanoparticles in nanomedicine: a review of recent advances","volume":"30","author":"Wu","year":"2019","journal-title":"Nanotechnology"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1395","doi-asserted-by":"crossref","DOI":"10.1016\/j.crgsc.2020.100042","article-title":"A review on synthesis, characterization and potential biological applications of superparamagnetic iron oxide nanoparticles","volume":"4","author":"Samrot","year":"2021","journal-title":"Curr. Res. Green Sustainable Chem."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1400","doi-asserted-by":"crossref","first-page":"21346","DOI":"10.1021\/am5063025","article-title":"Poly(2-Vinyl-4,4-dimethylazlactone)-functionalized magnetic nanoparticles as carriers for enzyme immobilization and its application","volume":"6","author":"Mu","year":"2014","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1405","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/21691401.2014.955107","article-title":"Application of gold nanoparticles in biomedical and drug delivery","volume":"44","author":"Daraee","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1410","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jddst.2018.02.007","article-title":"Gold nanoparticle mediated delivery of fungal asparaginase against cancer cells","volume":"44","author":"Baskar","year":"2018","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1415","doi-asserted-by":"crossref","first-page":"15394","DOI":"10.1016\/j.jmrt.2020.10.021","article-title":"Immobilization of l-asparaginase on gold nanoparticles for novel drug delivery approach as anti-cancer agent against human breast carcinoma cells","volume":"9","author":"Al-Dulimi","year":"2020","journal-title":"J. Mater. Res. Technol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1420","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10904-016-0448-x","article-title":"Synthesis and characterization of Asparaginase bound silver nanocomposite against ovarian Cancer cell line A2780 and lung Cancer cell line A549","volume":"27","author":"Baskar","year":"2017","journal-title":"J. Inorg. Organomet. Polym. Mater."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1425","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12079-018-0492-0","article-title":"Protein PEGylation for cancer therapy: bench to bedside","volume":"13","author":"Gupta","year":"2019","journal-title":"J. Cell Commun. Signal."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1430","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0142-9612(00)00193-9","article-title":"Peptide and protein PEGylation: a review of problems and solutions","volume":"22","author":"Veronese","year":"2001","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1435","series-title":"Drug Resist. Leuk. Lymphoma III","first-page":"621","article-title":"The three Asparaginases","author":"Asselin","year":"1999"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1440","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1158\/1078-0432.CCR-19-2975","article-title":"Space for Calaspargase? A new Asparaginase for acute lymphoblastic leukemia","volume":"26","author":"Lew","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1445","doi-asserted-by":"crossref","unstructured":"Clinical pharmacology of polyethylene glycol-L-asparaginase | Drug Metab. Dispos., (n.d.). https:\/\/dmd.aspetjournals.org\/content\/14\/3\/349.long (accessed June 28, 2024).","DOI":"10.1016\/S0090-9556(25)08348-5"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1450","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","article-title":"Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: children\u2019s Cancer group study CCG-1961","volume":"26","author":"Panosyan","year":"2004","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1455","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","volume":"31","author":"Vrooman","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1460","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1182\/blood.V128.22.175.175","article-title":"Randomized study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in pediatric patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma: results of DFCI ALL consortium protocol 11-001","volume":"128","author":"Silverman","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1465","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1182\/blood.V128.22.1629.1629","volume":"128","author":"Park","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1470","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.V124.21.936.936","article-title":"Frequency and characteristics of Pegaspargase antibodies in adults treated with a pediatric acute lymphoblastic leukemia regimen","volume":"124","author":"Burke","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1475","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2014.55.5763","article-title":"Pharmacokinetic and Pharmacodynamic properties of Calaspargase Pegol Escherichia coli L-Asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from children\u2019s oncology group study AALL07P4","volume":"32","author":"Angiolillo","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1480","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3324\/haematol.2024.286549","article-title":"Calaspargase pegol and pegaspargase cause similar hepatosteatosis in mice","volume":"110","author":"Ruiz-Torres","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1485","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1490","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.18.02439","article-title":"Antibodies predict Pegaspargase allergic reactions and failure of Rechallenge","volume":"37","author":"Liu","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149664_bb1495","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3324\/haematol.2020.258525","article-title":"Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. Coli asparaginase in children with acute lymphocytic leukemia","volume":"107","author":"Khalil","year":"2022","journal-title":"Haematologica"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025102213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025102213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T14:44:43Z","timestamp":1769179483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025102213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":298,"alternative-id":["S0141813025102213"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.149664","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging advancements to improve L-asparaginase-based therapy: New insight into old paradigm, a review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.149664","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"149664"}}